SCHEMBL383128

SCHEMBL383128

O=C1N=C[N]c2sccc21

nearest known ligand 0.37

Predicted protein targets (top 2)

geneUniProtsupporting neighboursconfidence
CES1 P23141 1/20 0.37
PTPRC P08575 1/20 0.31

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL18304700 0.83 CES1 (0.37) CES1PTPRC
SCHEMBL384425 0.71 CES1 (0.37) CES1PTPRC
SCHEMBL17837293 0.65
SCHEMBL38440 0.64
SCHEMBL2423612 0.62 CDC7 (0.33) CES1
SCHEMBL169947 0.61 CES1 (0.35) CES1PTPRC
SCHEMBL332780 0.61 GSK3B (0.37) CES1PTPRC
SCHEMBL336074 0.60
SCHEMBL2202905 0.58 CES1 (0.52) CES1PTPRC
SCHEMBL209366 0.56 S100A4 (0.42) CES1PTPRC

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 219 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
EP-0620813-A1 HETEROCYCLIC SULFONAMIDE DERIVATIVES AS ANTAGONISTS OF PAF AND ANGIOTENSIN II BRITISH BIO-TECHNOLOGY LIMITED (GB) 1994-10-26 EP claimed
WO-1993014069-A1 HETEROCYCLIC SULFONAMIDE DERIVATIVES AS ANTAGONISTS OF PAF AND ANGIOTENSIN II BRITISH BIO-TECHNOLOGY LIMITED (GB) 1993-07-22 WO claimed
US-20240228499-A1 MASP-2 INHIBITORS AND METHODS OF USE OMEROS CORPORATION (US) 2024-07-11 US disclosed
US-12030853-B2 MASP-2 inhibitors and methods of use OMEROS CORPORATION (US) 2024-07-09 US disclosed
US-20240207423-A1 PROGAMMABLE POLYMERIC DRUGS SONY GROUP CORP (JP) 2024-06-27 US disclosed
US-20240210408-A1 USE OF DIVALENT METALS FOR ENHANCEMENT OF FLUORESCENT SIGNALS SONY GROUP CORP (JP) 2024-06-27 US disclosed
US-12018159-B2 Ultra bright dimeric or polymeric dyes and methods for preparation of the same Sony Group Corporation (JP) 2024-06-25 US disclosed
US-12006438-B2 Polymeric dyes with linker groups comprising deoxyribose Sony Group Corporation (JP) 2024-06-11 US disclosed
WO-2024118840-A1 FUSED PYRIMIDINES AS MASP-2 INHIBITORS OMEROS CORPORATION (US) 2024-06-06 WO disclosed
WO-2024110803-A1 POLYMERIC COMPOUNDS COMPRISING ANTINEOPLASTIC AGENTS Sony Group Corporation (JP) 2024-05-30 WO disclosed
US-11981820-B2 Ultra bright dimeric or polymeric dyes Sony Group Corporation (JP) 2024-05-14 US disclosed
US-8415370-B2 Spiro-oxindole compounds and their uses as therapeutic agents XENON PHARMACEUTICALS INC. (CA) 2013-04-09 US disclosed
US-20120295897-A1 SPIRO-OXINDOLE COMPOUNDS AND THEIR USES AS THERAPEUTIC AGENTS XENON PHARMACEUTICALS INC. (CA) 2012-11-22 US disclosed
US-8101647-B2 Spiro-oxindole compounds and their use as therapeutic agents XENON PHARMACEUTICALS INC. (CA) 2012-01-24 US disclosed
US-20110144139-A1 HEPSIN INHIBITORS FRED HUTCHINSON CANCER RESEARCH CENTER 2011-06-16 US disclosed
US-20110112162-A9 SPIRO-OXINDOLE COMPOUNDS AND THEIR USE AS THERAPEUTIC AGENTS XENON PHARMACEUTICALS INC. (CA) 2011-05-12 US disclosed
US-20100099728-A1 SPIRO-OXINDOLE COMPOUNDS AND THEIR USE AS THERAPEUTIC AGENTS XENON PHARMACEUTICALS INC. (CA) 2010-04-22 US disclosed
CN-101014594-A Piperidine derivatives as renin inhibitors SPEEDEL EXPERIMENTA AG (CH) 2007-08-08 CN disclosed
EP-0620813-A1 HETEROCYCLIC SULFONAMIDE DERIVATIVES AS ANTAGONISTS OF PAF AND ANGIOTENSIN II BRITISH BIO-TECHNOLOGY LIMITED (GB) 1994-10-26 EP disclosed
WO-1993014069-A1 HETEROCYCLIC SULFONAMIDE DERIVATIVES AS ANTAGONISTS OF PAF AND ANGIOTENSIN II BRITISH BIO-TECHNOLOGY LIMITED (GB) 1993-07-22 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (9 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20240228499-A1 MASP-2 INHIBITORS AND METHODS OF USE MASP2, SPINT2, SERPINB1 CES1 1728/4885PTPRC 1730/4885
US-11981820-B2 Ultra bright dimeric or polymeric dyes IK, MRPS2, UFM1 CES1 4474/4885PTPRC 3331/4885
US-20110112162-A9 SPIRO-OXINDOLE COMPOUNDS AND THEIR USE AS THERAPEUTIC AGENTS TRPV3, TRPV1, TRPC3 CES1 3034/4885PTPRC 1189/4885
US-20110144139-A1 HEPSIN INHIBITORS HPN, TMPRSS2, SPINT2 CES1 232/4885PTPRC 2484/4885
US-20240207423-A1 PROGAMMABLE POLYMERIC DRUGS OPRM1, CHRM1, TUBB3 CES1 1331/4885PTPRC 2179/4885
US-12006438-B2 Polymeric dyes with linker groups comprising deoxyribose H1-0, POLM, H1-2 CES1 3979/4885PTPRC 4177/4885
US-20100099728-A1 SPIRO-OXINDOLE COMPOUNDS AND THEIR USE AS THERAPEUTIC AGENTS TRPV3, TRPV1, TRPC3 CES1 3034/4885PTPRC 1189/4885
US-20120295897-A1 SPIRO-OXINDOLE COMPOUNDS AND THEIR USES AS THERAPEUTIC AGENTS TRPV3, TRPC3, TRPV1 CES1 3090/4885PTPRC 1125/4885
US-12030853-B2 MASP-2 inhibitors and methods of use MASP2, METAP2, SPINT2 CES1 1587/4885PTPRC 1071/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.